nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADK—Purine salvage—APRT—nephrolithiasis	0.143	0.296	CbGpPWpGaD
Vidarabine—ADA—Purine salvage—APRT—nephrolithiasis	0.0973	0.201	CbGpPWpGaD
Vidarabine—ADK—Purine metabolism—APRT—nephrolithiasis	0.068	0.14	CbGpPWpGaD
Vidarabine—ADA—Purine metabolism—APRT—nephrolithiasis	0.0462	0.0954	CbGpPWpGaD
Vidarabine—Atrioventricular block second degree—Hydrochlorothiazide—nephrolithiasis	0.0448	0.11	CcSEcCtD
Vidarabine—Atrioventricular block complete—Hydrochlorothiazide—nephrolithiasis	0.0366	0.0901	CcSEcCtD
Vidarabine—ADK—Nucleotide metabolism—APRT—nephrolithiasis	0.0342	0.0705	CbGpPWpGaD
Vidarabine—Adenosine monophosphate—APRT—nephrolithiasis	0.024	1	CrCbGaD
Vidarabine—ADA—Nucleotide metabolism—APRT—nephrolithiasis	0.0232	0.0479	CbGpPWpGaD
Vidarabine—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.0173	0.0425	CcSEcCtD
Vidarabine—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0167	0.0411	CcSEcCtD
Vidarabine—Numbness—Hydrochlorothiazide—nephrolithiasis	0.0154	0.038	CcSEcCtD
Vidarabine—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.0148	0.0363	CcSEcCtD
Vidarabine—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0315	CcSEcCtD
Vidarabine—ADA—renal system—nephrolithiasis	0.0114	0.134	CbGeAlD
Vidarabine—ADK—nephron tubule—nephrolithiasis	0.0103	0.121	CbGeAlD
Vidarabine—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0251	CcSEcCtD
Vidarabine—DPP4—nephron tubule—nephrolithiasis	0.00995	0.117	CbGeAlD
Vidarabine—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0098	0.0241	CcSEcCtD
Vidarabine—ADK—renal system—nephrolithiasis	0.00933	0.11	CbGeAlD
Vidarabine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00914	0.0225	CcSEcCtD
Vidarabine—DPP4—renal system—nephrolithiasis	0.00905	0.106	CbGeAlD
Vidarabine—ADK—kidney—nephrolithiasis	0.00902	0.106	CbGeAlD
Vidarabine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.0088	0.0216	CcSEcCtD
Vidarabine—ADK—cortex of kidney—nephrolithiasis	0.00878	0.103	CbGeAlD
Vidarabine—DPP4—kidney—nephrolithiasis	0.00874	0.103	CbGeAlD
Vidarabine—DPP4—cortex of kidney—nephrolithiasis	0.00852	0.1	CbGeAlD
Vidarabine—ADORA2A—GPCRs, Other—CHRM3—nephrolithiasis	0.0076	0.0157	CbGpPWpGaD
Vidarabine—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00741	0.0182	CcSEcCtD
Vidarabine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00705	0.0174	CcSEcCtD
Vidarabine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00701	0.0173	CcSEcCtD
Vidarabine—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00686	0.0169	CcSEcCtD
Vidarabine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00654	0.0161	CcSEcCtD
Vidarabine—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00639	0.0157	CcSEcCtD
Vidarabine—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00599	0.0147	CcSEcCtD
Vidarabine—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00596	0.0147	CcSEcCtD
Vidarabine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00574	0.0141	CcSEcCtD
Vidarabine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00549	0.0135	CcSEcCtD
Vidarabine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00548	0.0135	CcSEcCtD
Vidarabine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00543	0.0134	CcSEcCtD
Vidarabine—ADORA2A—G alpha (s) signalling events—PTH—nephrolithiasis	0.00542	0.0112	CbGpPWpGaD
Vidarabine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00541	0.0133	CcSEcCtD
Vidarabine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00527	0.013	CcSEcCtD
Vidarabine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00524	0.0129	CcSEcCtD
Vidarabine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00514	0.0126	CcSEcCtD
Vidarabine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00511	0.0126	CcSEcCtD
Vidarabine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00501	0.0123	CcSEcCtD
Vidarabine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00494	0.0122	CcSEcCtD
Vidarabine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00492	0.0121	CcSEcCtD
Vidarabine—Cough—Hydrochlorothiazide—nephrolithiasis	0.00488	0.012	CcSEcCtD
Vidarabine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00476	0.0117	CcSEcCtD
Vidarabine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00474	0.0117	CcSEcCtD
Vidarabine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.0047	0.0116	CcSEcCtD
Vidarabine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00466	0.0115	CcSEcCtD
Vidarabine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00456	0.0112	CcSEcCtD
Vidarabine—Shock—Hydrochlorothiazide—nephrolithiasis	0.00449	0.011	CcSEcCtD
Vidarabine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00445	0.011	CcSEcCtD
Vidarabine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00441	0.0109	CcSEcCtD
Vidarabine—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00426	0.0105	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00416	0.0102	CcSEcCtD
Vidarabine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.0041	0.0101	CcSEcCtD
Vidarabine—ADK—Metabolism—GRHPR—nephrolithiasis	0.00409	0.00845	CbGpPWpGaD
Vidarabine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00407	0.01	CcSEcCtD
Vidarabine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00406	0.00998	CcSEcCtD
Vidarabine—Pain—Hydrochlorothiazide—nephrolithiasis	0.0039	0.0096	CcSEcCtD
Vidarabine—ADK—Metabolism—AGXT—nephrolithiasis	0.00365	0.00753	CbGpPWpGaD
Vidarabine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00363	0.00892	CcSEcCtD
Vidarabine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00336	0.00827	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0033	0.00681	CbGpPWpGaD
Vidarabine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00806	CcSEcCtD
Vidarabine—ADK—Metabolism—SLC26A1—nephrolithiasis	0.0031	0.0064	CbGpPWpGaD
Vidarabine—ADK—Metabolism—APRT—nephrolithiasis	0.0031	0.0064	CbGpPWpGaD
Vidarabine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00302	0.00743	CcSEcCtD
Vidarabine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.0029	0.00714	CcSEcCtD
Vidarabine—Rash—Hydrochlorothiazide—nephrolithiasis	0.00288	0.00708	CcSEcCtD
Vidarabine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00287	0.00707	CcSEcCtD
Vidarabine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00286	0.00703	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00283	0.00583	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GRHPR—nephrolithiasis	0.00278	0.00574	CbGpPWpGaD
Vidarabine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00271	0.00667	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00249	0.00514	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AGXT—nephrolithiasis	0.00248	0.00512	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00226	0.00467	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AQP1—nephrolithiasis	0.00221	0.00456	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00215	0.00444	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC26A1—nephrolithiasis	0.00211	0.00435	CbGpPWpGaD
Vidarabine—ADA—Metabolism—APRT—nephrolithiasis	0.00211	0.00435	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CHRM3—nephrolithiasis	0.002	0.00413	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—PTH—nephrolithiasis	0.00197	0.00406	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.00168	0.00347	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADCY10—nephrolithiasis	0.00157	0.00324	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—DGKH—nephrolithiasis	0.00153	0.00315	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AQP1—nephrolithiasis	0.0015	0.0031	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CHRM3—nephrolithiasis	0.00136	0.0028	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RGS14—nephrolithiasis	0.00134	0.00276	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00122	0.00251	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PTH—nephrolithiasis	0.00111	0.0023	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.0011	0.00228	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTH—nephrolithiasis	0.00101	0.00209	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000903	0.00186	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—DGKH—nephrolithiasis	0.000903	0.00186	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000653	0.00135	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTH—nephrolithiasis	0.000597	0.00123	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SPP1—nephrolithiasis	0.0003	0.000618	CbGpPWpGaD
